What's Happening?
Delphi Diagnostics announced the publication of new clinical data in the European Journal of Cancer, validating the Endocrine Activity Index Recurrence Risk (EAI RR) as a significant predictor of outcomes in hormone receptor-positive, node-positive breast
cancer patients. The study analyzed 659 patient samples from the PACS-01 clinical trial, demonstrating that EAI RR provides meaningful prognostic and endocrine-predictive information beyond the 21-gene Recurrence Score. The findings position EAI as a differentiated biomarker that captures endocrine biology, enhancing risk stratification and informing management decisions in breast cancer treatment.
Why It's Important?
The validation of EAI RR as a prognostic tool represents a significant advancement in personalized breast cancer treatment. By providing independent prognostic information, EAI RR can help clinicians tailor treatment plans more effectively, potentially improving patient outcomes. This development is crucial for the healthcare industry, as it highlights the importance of biomarkers in cancer prognosis and treatment personalization. The ability to predict endocrine therapy benefits could lead to more targeted and effective treatment strategies, benefiting patients and healthcare providers.
